^
    4ms
    Leveraging Pillar Biosciences Targeted NGS Panels as a Rapid Front-Line Strategy to Inform and Accelerate the Delivery of Precision Medicine (AMP 2024)
    In this workshop we review the development, validation and clinical implementation of Pillar Biosciences' rapid 21-gene solid tumor & heme panel oncoReveal Nexus by Memorial Sloan Kettering Cancer Center (MSKCC). We will review this assay's concordance with the MSKCC's MSK-IMPACT® panels and discuss how this type of rapid testing can be leveraged by other clinical laboratories as tool to help sub-select and inform which patients should have CGP testing performed.
    Next-generation sequencing
    |
    MSK-IMPACT • oncoReveal™ Nexus
    4ms
    Pillar Biosciences launches oncoReveal™ Nexus to help accelerate the delivery of targeted therapy (Pillar Biosciences Press Release)
    "Pillar Biosciences, Inc...has announced the global launch of oncoReveal™ Nexus, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a rapid, targeted solution for solid and hematological malignancies to help accelerate the delivery of targeted therapy...A team at New York’s Memorial Sloan Kettering Cancer Center (MSK), will be the first to utilize oncoReveal™ Nexus, which will be branded MSK-REACT. MSK has already received NYS DOH approval for clinical implementation of MSK-REACT, enabling a more streamlined NGS workflow to help patients get on the right therapy sooner."
    Launch
    |
    oncoReveal™ Nexus